Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Editor-in-Chief Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS discusses this agent as a potential tool for preexposure prophylaxis (PrEP) against HIV infection. And if it is approved, the ability to overcome access issues in low to middle income countries that have a greater need.

In the latest issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the continuous antibiotic trade-off of targeted vs broad spectrum therapies and cheap vs expensive options as they relate to UTI treatment.

In the October Editor-in-Chief letter, Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS, writes about this novel antibiotic indicated for a targeted, resistant pathogen and its long-term viability.

With recent reports of this vector-borne illness in the continental United States, there is concern this might become endemic in the country again.

As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.

Two RSV vaccines for seniors have completed phase 3 trials and demonstrated beneficial results. FDA decisions on potential approvals for both could be forthcoming in the next few weeks.

As COVID-19 evolves, learning how to live with a virus that has become endemic will have its challenges, but medical science will help the public be able to accept it.

Editor-in-Chief Jason Gallagher discusses the surging number of cases of influenza and RSV while there is a concomitant shortage of amoxicillin suspension.

Our cover story for the October 2022 print edition of Contagion details the original coronavirus.

The Paxlovid approval reaffirms the importance of pharmacists in fighting COVID-19.

Here is a review of the literature for this class of antibiotics.

With few exceptions, COVID-19 therapies have not been studied comparatively, so choosing therapies to preferentially recommend is difficult and is done, instead, by strength of evidence and quality of data.

As we recently surpassed the 2-year mark of the pandemic, the May issue reflects on lessons learned thus far.

The idea of a future with COVID-19 is settling in, and building strategies that improve quality of life as we live with this viral disease are paramount.

Drs Angela Rasmussen and Donald Alcendor detail the roadblocks facing COVID-19 booster shots.

A panel of doctors explains whether or not someone can get a different COVID-19 booster from their original vaccinations and how they compare.

Experts discuss who is eligible for COVID-19 booster shots and the misinformation around COVID-19 vaccinations.

Angela Rasmussen, PhD, and Donald Alcendor, PhD have a conversation on the recent expansion of COVID-19 booster shot usage in eligible populations.

Key opinion leaders debate on the necessity of COVID-19 booster shots.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

Our editor-in-chief rates the first year of response to the pandemic.

The US Food and Drug Administration approved imipenem-cilastatin-relebactam to treat complicated intra-abdominal infections and complicated urinary tract infections in adults with limited treatment options.